Royal Bank of Canada Boosts Edwards Lifesciences (NYSE:EW) Price Target to $101.00

Edwards Lifesciences (NYSE:EW - Get Free Report) had its price objective lifted by stock analysts at Royal Bank of Canada from $95.00 to $101.00 in a report issued on Monday, Benzinga reports. The firm presently has an "outperform" rating on the medical research company's stock. Royal Bank of Canada's price target suggests a potential upside of 13.23% from the company's previous close.

A number of other brokerages have also weighed in on EW. OTR Global raised shares of Edwards Lifesciences from a "mixed" rating to a "positive" rating in a research note on Tuesday, March 26th. Citigroup boosted their target price on Edwards Lifesciences from $90.00 to $98.00 and gave the company a "neutral" rating in a research note on Wednesday, April 3rd. Evercore ISI raised their price target on shares of Edwards Lifesciences from $86.00 to $92.00 and gave the stock an "in-line" rating in a research note on Thursday, April 4th. Morgan Stanley boosted their price objective on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an "overweight" rating in a research report on Thursday, March 21st. Finally, Wells Fargo & Company raised shares of Edwards Lifesciences from an "equal weight" rating to an "overweight" rating and set a $94.00 target price for the company in a research report on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $91.73.

Edwards Lifesciences Trading Down 1.2 %

Shares of EW traded down $1.08 during trading hours on Monday, reaching $89.20. The stock had a trading volume of 2,845,478 shares, compared to its average volume of 3,906,282. The firm has a 50-day moving average of $90.01 and a 200 day moving average of $77.79. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. The company has a market cap of $53.69 billion, a P/E ratio of 38.90, a P/E/G ratio of 4.47 and a beta of 1.05. Edwards Lifesciences has a 52 week low of $60.57 and a 52 week high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.64. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.50 billion. During the same period in the prior year, the company earned $0.64 earnings per share. The company's revenue for the quarter was up 13.3% compared to the same quarter last year. On average, sell-side analysts expect that Edwards Lifesciences will post 2.76 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the sale, the chief financial officer now directly owns 19,248 shares of the company's stock, valued at approximately $1,506,925.92. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Edwards Lifesciences news, Director Michael A. Mussallem sold 29,350 shares of the stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $92.42, for a total transaction of $2,712,527.00. Following the transaction, the director now owns 4,486 shares in the company, valued at approximately $414,596.12. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the sale, the chief financial officer now owns 19,248 shares of the company's stock, valued at $1,506,925.92. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 194,004 shares of company stock worth $17,166,254. Insiders own 1.29% of the company's stock.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds have recently added to or reduced their stakes in the stock. Brookstone Capital Management raised its position in shares of Edwards Lifesciences by 3.2% in the 1st quarter. Brookstone Capital Management now owns 12,275 shares of the medical research company's stock valued at $1,173,000 after buying an additional 383 shares in the last quarter. Ehrlich Financial Group lifted its stake in Edwards Lifesciences by 62.6% during the first quarter. Ehrlich Financial Group now owns 6,728 shares of the medical research company's stock worth $643,000 after purchasing an additional 2,591 shares during the last quarter. First Financial Corp IN boosted its holdings in shares of Edwards Lifesciences by 50.0% in the 1st quarter. First Financial Corp IN now owns 1,431 shares of the medical research company's stock valued at $137,000 after purchasing an additional 477 shares in the last quarter. Riverview Trust Co bought a new position in shares of Edwards Lifesciences in the 1st quarter valued at $34,000. Finally, Central Valley Advisors LLC increased its stake in shares of Edwards Lifesciences by 10.9% in the 1st quarter. Central Valley Advisors LLC now owns 13,905 shares of the medical research company's stock valued at $1,329,000 after purchasing an additional 1,367 shares during the last quarter. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.